- Zacks•7 days ago
Aradigm Corporation is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
- Business Wire•7 days agoAradigm Announces Last Patient Dosing Visit in ORBIT-3 and ORBIT-4 Phase 3 Studies of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis Patients
Aradigm Corporation today announced that the last patient has completed the final dosing visit in the ORBIT-3 and ORBIT-4 Phase 3 clinical studies of Pulmaquin®, Aradigm’s proprietary inhaled ciprofloxacin, an investigational new medication being studied for the treatment of patients with non-cystic fibrosis bronchiectasis who have chronic lung infections with Pseudomonas aeruginosa.
- Business Wire•8 days ago
Aradigm Corporation announced today that it will host an Analyst Lunch on the topic of Non-Cystic Fibrosis Bronchiectasis on Monday, September 26, 2016 from 12:00-1:30 pm Eastern Time in New York, NY.
Aradigm Corporation (ARDM)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||6.30 x 3000|
|Ask||7.28 x 1000|
|Day's Range||6.50 - 6.88|
|52wk Range||2.60 - 7.26|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-3.07|
|Avg Vol (3m)||10,876|
|Dividend & Yield||0.00 (0.00%)|